HK1134042A1 - Identification of a micro-rna that activates expression of - Google Patents
Identification of a micro-rna that activates expression ofInfo
- Publication number
- HK1134042A1 HK1134042A1 HK10102134.1A HK10102134A HK1134042A1 HK 1134042 A1 HK1134042 A1 HK 1134042A1 HK 10102134 A HK10102134 A HK 10102134A HK 1134042 A1 HK1134042 A1 HK 1134042A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- identification
- rna
- micro
- treatment
- function
- Prior art date
Links
- 108091070501 miRNA Proteins 0.000 title 1
- 239000000835 fiber Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108010068426 Contractile Proteins Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020880 Hypertrophy Diseases 0.000 abstract 1
- 108091092539 MiR-208 Proteins 0.000 abstract 1
- 108700011259 MicroRNAs Proteins 0.000 abstract 1
- 208000023178 Musculoskeletal disease Diseases 0.000 abstract 1
- 230000003416 augmentation Effects 0.000 abstract 1
- 230000009787 cardiac fibrosis Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Environmental Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83466706P | 2006-08-01 | 2006-08-01 | |
US95291107P | 2007-07-31 | 2007-07-31 | |
US95291707P | 2007-07-31 | 2007-07-31 | |
PCT/US2007/074866 WO2008016924A2 (en) | 2006-08-01 | 2007-07-31 | Identification of a micro-rna that activates expression of beta-myosin heavy chain |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1134042A1 true HK1134042A1 (en) | 2010-04-16 |
Family
ID=38896739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10102134.1A HK1134042A1 (en) | 2006-08-01 | 2010-03-01 | Identification of a micro-rna that activates expression of |
Country Status (17)
Country | Link |
---|---|
US (1) | US8304397B2 (pt) |
EP (2) | EP2434017A3 (pt) |
JP (2) | JP5718570B2 (pt) |
KR (1) | KR101485495B1 (pt) |
CN (1) | CN101522222B (pt) |
AU (1) | AU2007281261B2 (pt) |
BR (1) | BRPI0714794A2 (pt) |
CA (1) | CA2659364C (pt) |
CY (1) | CY1113539T1 (pt) |
DK (1) | DK2056882T3 (pt) |
ES (1) | ES2397439T3 (pt) |
HK (1) | HK1134042A1 (pt) |
MX (1) | MX2009001281A (pt) |
NZ (1) | NZ574563A (pt) |
PL (1) | PL2056882T3 (pt) |
PT (1) | PT2056882E (pt) |
WO (1) | WO2008016924A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ574563A (en) | 2006-08-01 | 2012-02-24 | Univ Texas | IDENTIFICATION OF A MICRO-RNA (miR-208) THAT ACTIVATES EXPRESSION OF BETA-MYOSIN HEAVY CHAIN FOR USE IN CARDIAC HYPERTROPHY CONDITIONS |
WO2008042231A2 (en) * | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
WO2008063919A2 (en) * | 2006-11-10 | 2008-05-29 | The Uab Research Foundation | A microrna mediator of cardiomyopathy and heart failure |
EA200900782A1 (ru) * | 2006-12-14 | 2009-12-30 | Новартис Аг | Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений |
KR101554996B1 (ko) | 2007-07-31 | 2015-09-23 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 섬유증을 조절하는 마이크로-rna 집단 및 이의 용도 |
NZ598702A (en) * | 2007-07-31 | 2014-01-31 | Univ Texas | A micro-rna family that modulates fibrosis and uses thereof |
WO2009018492A2 (en) | 2007-07-31 | 2009-02-05 | The Board Of Regents Of The University Of Texas System | Micro-rnas that control myosin expression and myofiber identity |
WO2010026213A2 (en) * | 2008-09-04 | 2010-03-11 | Universität Zürich Prorektorat Mnw | Treatment of scleroderma |
WO2010091204A1 (en) | 2009-02-04 | 2010-08-12 | Board Of Regents, The University Of Texas System | Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders |
CA2761106C (en) | 2009-05-05 | 2019-01-15 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
WO2011154553A2 (en) * | 2010-06-11 | 2011-12-15 | Cellartis Ab | Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
JP5995855B2 (ja) | 2010-11-05 | 2016-09-21 | ミラゲン セラピューティクス,インコーポレイテッド | 塩基修飾オリゴヌクレオチド |
KR20140004646A (ko) * | 2010-12-15 | 2014-01-13 | 미라젠 세러퓨틱스 | 잠금 뉴클레오티드를 포함하는 마이크로rna 억제제 |
WO2013034653A1 (en) * | 2011-09-06 | 2013-03-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | The mirna-212/132 family as a therapeutic target |
CA2850223A1 (en) * | 2011-10-06 | 2013-04-11 | Eva Van Rooij | Control of whole body energy homeostasis by microrna regulation |
CN104685056A (zh) | 2012-06-21 | 2015-06-03 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
CN102719436A (zh) * | 2012-06-27 | 2012-10-10 | 南开大学 | 一种寡核苷酸及其制备在防治心肌肥大与心力衰竭药物中的用途 |
US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
WO2014151835A1 (en) | 2013-03-15 | 2014-09-25 | Miragen Therapeutics, Inc | Locked nucleic acid inhibitor of mir-145 and uses thereof |
GB201400598D0 (en) | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
EA201791644A1 (ru) | 2015-01-20 | 2018-01-31 | Мираджен Терапьютикс, Инк. | Ингибиторы mir-92 и их применение |
CN105695606B (zh) * | 2016-04-07 | 2020-08-28 | 昆明理工大学 | 用于非治疗目的的肥厚型心肌病相关致病基因突变的筛查方法 |
US10150115B2 (en) * | 2016-07-21 | 2018-12-11 | Spacepharma SA | System and method for rehydrating powder and delivering the rehydrated powder to a reactor |
WO2018047148A1 (en) | 2016-09-12 | 2018-03-15 | Novartis Ag | Compounds for the inhibition of mirna |
CN109097461B (zh) * | 2018-09-06 | 2021-07-30 | 北京中关村生命科学园生物医药科技孵化有限公司 | 一种心肌病相关基因检测试剂及其应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
TW215434B (pt) | 1992-03-07 | 1993-11-01 | Hoechst Ag | |
US5844107A (en) | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
DE69535853D1 (de) | 1994-03-23 | 2008-11-20 | Univ Case Western Reserve | Kompaktnukleinsäure und ihre verabreichung in zellen |
US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
AU733883B2 (en) | 1997-02-04 | 2001-05-31 | Bristol-Myers Squibb Company | Dihydropyrimidone derivatives as NPY antagonists |
EP1180016B1 (en) | 1999-05-24 | 2006-09-27 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
AU6794700A (en) * | 1999-08-20 | 2001-03-19 | Board Of Regents, The University Of Texas System | Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression |
DE10004858A1 (de) * | 2000-02-03 | 2001-08-16 | Schering Ag | Verwendung von Proteinkinase-Inhibitor-alpha |
US20020042388A1 (en) | 2001-05-01 | 2002-04-11 | Cooper Mark J. | Lyophilizable and enhanced compacted nucleic acids |
WO2002032396A2 (en) | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for delivery of nucleic acids |
CA2445947A1 (en) | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
US20050124568A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
EP2386637B1 (en) * | 2001-09-28 | 2018-05-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
US7781415B2 (en) * | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
CA2533701A1 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2005047505A2 (en) * | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性rnaが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
CA2535585A1 (en) * | 2003-08-21 | 2005-03-03 | Osaka University | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
CA2554818A1 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
WO2005079397A2 (en) | 2004-02-13 | 2005-09-01 | Rockefeller University | Anti-microrna oligonucleotide molecules |
EP1771563A2 (en) | 2004-05-28 | 2007-04-11 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
ES2534301T3 (es) * | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
US20070099196A1 (en) | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
US8071306B2 (en) * | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
EP1874936B1 (en) | 2005-04-19 | 2013-10-30 | BASF Plant Science GmbH | Improved methods controlling gene expression |
EP2002003B1 (en) | 2005-05-27 | 2015-12-30 | Ospedale San Raffaele S.r.l. | Gene vector comprising mi-rna |
US20070087179A1 (en) * | 2005-10-17 | 2007-04-19 | Horn Donald R | Solid surface composite |
EP2671949A1 (en) | 2005-12-12 | 2013-12-11 | University Of North Carolina At Chapel Hill | Micro-RNA miR-145 that regulate muscle cell proliferation and differentiation |
US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
AU2007234191B2 (en) | 2006-04-03 | 2012-07-12 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides |
NZ574563A (en) | 2006-08-01 | 2012-02-24 | Univ Texas | IDENTIFICATION OF A MICRO-RNA (miR-208) THAT ACTIVATES EXPRESSION OF BETA-MYOSIN HEAVY CHAIN FOR USE IN CARDIAC HYPERTROPHY CONDITIONS |
WO2008042231A2 (en) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
AU2007306594A1 (en) | 2006-10-09 | 2008-04-17 | Julius-Maximilians-Universitat Wurzburg | MicroRNA (miRNA) for the diagnosis and treatment of heart diseases |
JP2010509923A (ja) | 2006-11-23 | 2010-04-02 | ミルクス セラピューティクス アンパーツゼルスカブ | 標的rnaの活性を変化させるためのオリゴヌクレオチド |
EA200900782A1 (ru) | 2006-12-14 | 2009-12-30 | Новартис Аг | Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений |
US20090137504A1 (en) | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
WO2008147837A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas |
EP2192925A4 (en) | 2007-08-23 | 2013-04-03 | Keren Pharmaceuticals | TARGETING RNA WITH EXTERNAL GUIDE SEQUENCES |
-
2007
- 2007-07-31 NZ NZ574563A patent/NZ574563A/en not_active IP Right Cessation
- 2007-07-31 JP JP2009523016A patent/JP5718570B2/ja not_active Expired - Fee Related
- 2007-07-31 BR BRPI0714794-5A patent/BRPI0714794A2/pt not_active Application Discontinuation
- 2007-07-31 ES ES07813595T patent/ES2397439T3/es active Active
- 2007-07-31 CA CA2659364A patent/CA2659364C/en not_active Expired - Fee Related
- 2007-07-31 US US11/831,427 patent/US8304397B2/en not_active Expired - Fee Related
- 2007-07-31 PT PT07813595T patent/PT2056882E/pt unknown
- 2007-07-31 WO PCT/US2007/074866 patent/WO2008016924A2/en active Application Filing
- 2007-07-31 PL PL07813595T patent/PL2056882T3/pl unknown
- 2007-07-31 EP EP11190352A patent/EP2434017A3/en not_active Withdrawn
- 2007-07-31 KR KR1020097004411A patent/KR101485495B1/ko not_active IP Right Cessation
- 2007-07-31 DK DK07813595.1T patent/DK2056882T3/da active
- 2007-07-31 MX MX2009001281A patent/MX2009001281A/es active IP Right Grant
- 2007-07-31 EP EP07813595A patent/EP2056882B1/en not_active Not-in-force
- 2007-07-31 CN CN2007800367837A patent/CN101522222B/zh not_active Expired - Fee Related
- 2007-07-31 AU AU2007281261A patent/AU2007281261B2/en not_active Ceased
-
2010
- 2010-03-01 HK HK10102134.1A patent/HK1134042A1/xx not_active IP Right Cessation
-
2013
- 2013-01-11 CY CY20131100028T patent/CY1113539T1/el unknown
- 2013-09-30 JP JP2013203794A patent/JP5798165B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2434017A2 (en) | 2012-03-28 |
CA2659364C (en) | 2017-08-22 |
PT2056882E (pt) | 2012-11-19 |
DK2056882T3 (da) | 2012-11-19 |
EP2434017A3 (en) | 2012-09-05 |
PL2056882T3 (pl) | 2013-03-29 |
JP5798165B2 (ja) | 2015-10-21 |
AU2007281261A1 (en) | 2008-02-07 |
CY1113539T1 (el) | 2016-06-22 |
KR20090037968A (ko) | 2009-04-16 |
CN101522222A (zh) | 2009-09-02 |
JP2009545615A (ja) | 2009-12-24 |
AU2007281261B2 (en) | 2013-03-21 |
JP5718570B2 (ja) | 2015-05-13 |
US8304397B2 (en) | 2012-11-06 |
US20090180957A1 (en) | 2009-07-16 |
JP2014001243A (ja) | 2014-01-09 |
EP2056882A2 (en) | 2009-05-13 |
CA2659364A1 (en) | 2008-02-07 |
CN101522222B (zh) | 2012-04-18 |
MX2009001281A (es) | 2009-04-16 |
NZ574563A (en) | 2012-02-24 |
ES2397439T3 (es) | 2013-03-07 |
WO2008016924A2 (en) | 2008-02-07 |
WO2008016924A3 (en) | 2008-08-07 |
BRPI0714794A2 (pt) | 2013-05-21 |
EP2056882B1 (en) | 2012-10-24 |
KR101485495B1 (ko) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1134042A1 (en) | Identification of a micro-rna that activates expression of | |
WO2009058818A3 (en) | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling | |
MX2010001216A (es) | Microarn que controla la expresion de miosina y la identidad de miofibras. | |
MX2018003235A (es) | Composiciones de flavonoide y metodos de uso. | |
MX2010001217A (es) | Familia de micro-arn que modula la fibrosis y usos de la misma. | |
EA201201648A1 (ru) | Стимуляторы sgc | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
BR112012011586A2 (pt) | agentes de abrasão á base de matéria-prima natural com propriedades aperfeiçoadoras de reologia | |
PH12019500626A1 (en) | Aav treatment of huntington's disease | |
BRPI1010302A2 (pt) | composições e métodos para tratamento, inibição ou prevenção do desenvolvimento de uma doença patogênica de planta e método de extermínio, inibição ou prevenção do desenvolvimento de um organismo | |
BR112016029178A2 (pt) | composições e métodos para a expressão de rnas guia de crispr usando o promotor h1 | |
RS53513B1 (en) | GLYX-13 FOR USE IN THE REFRACTOR DEPRESSION TREATMENT PROCEDURE | |
WO2008156685A3 (en) | Tendon stem cells | |
AR100560A1 (es) | Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido | |
HK1139051A1 (en) | Methods of treating dyspnea associated with acute heart failure | |
PL2274054T3 (pl) | Pigment przetwarzany naturalnym estrem, woskiem lub olejem, sposób jego wytwarzania i kosmetyk z nim otrzymany | |
WO2009089635A9 (en) | Treating neurodegenerative diseases with progranulin (pgrn) | |
MX2010009888A (es) | Uso de un aceite secante para proteger el color frente al lavado de fibras queratinicas teñidas artificialmente; procesos de coloracion. | |
WO2019083281A3 (ko) | 신규한 근골격계 줄기세포 | |
IN2012DN02624A (pt) | ||
CY1113743T1 (el) | Παραγωγα ισοκινολινονης ως ανταγωνιστες toy νκ3 | |
UA100011C2 (ru) | Применение хитозанов для нетерапевтического способа ускорения скорости роста ногтей | |
EA024696B9 (ru) | Способ обработки волос | |
WO2010000851A3 (en) | Methods for modulating angiogenesis via dystrophin dp71 | |
EA201290504A1 (ru) | Новые производные (конденсированный гетероцикл-пиперидин)-(пиперазинил)-1-алканона или (конденсированный гетероцикл-пирролидин)-(пиперазинил)-1-алканона и их применение в качестве ингибиторов р75 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170731 |